PrecisionLife at LSX World Congress 2025
April 28-30 2025 | London, UK
PrecisionLife is excited to be attending the upcoming LSX World Congress 2025 in London, one of Europe’s leading strategy, investment, and partnering events for life sciences executives.
As part of the event’s focus on deal-making and innovation in the biotech sector, our Co-founder and CBIO, Rowan Gardner, will be joining the expert panel discussion:
CNS & Neurology Success: Strategies for Enhanced Collaboration in Biotech and Pharma Partnerships
🗓️ Tuesday April 29 2025 | 🕒 3:00–3:40 PM BST | 📍 LSX World Congress, London
- Rowan Gardner, Co-founder & CBIO at PrecisionLife
- Olga Krylova, Head of Search & Evaluation, Europe, Global Business Development & Innovation at Otsuka
- Jenny Laird, VP, Search & Evaluation Neuroscience at Eli Lilly and Company
- Rupert Haynes, CEO at Avata Biosciences
- Sahil Kirpekar, Founder at Lumina Life Sciences
The panel will explore key strategies for successful partnering between biotech innovators and pharma companies in the CNS and neurology space — a focus area where PrecisionLife is delivering novel insights into the biology of complex chronic diseases and identifying high-value targets and biomarkers for precision therapeutics.
Alongside industry leaders from Otsuka, Eli Lilly, Avata Biosciences, and Lumina Life Sciences, Rowan will share perspectives on how our unique combinatorial analytics precision medicine platform and mechanism-based patient stratification biomarkers enable more effective drug discovery and development in CNS indications.
Meet with PrecisionLife at LSX World Congress
If you’re attending LSX World Congress and would like to connect with the PrecisionLife team to learn more about our disease insights and partnership opportunities, please get in touch via the event partnering system or reach out to us directly at bio@precisionlife.com.
We look forward to seeing you in London!
About PrecisionLife
PrecisionLife is a clinical-stage precision medicine company creating better diagnostic tools and more personalized treatment options to predict, treat, and prevent complex, chronic diseases.
We’ve completely reimagined how to analyze multiomic patient data, developing a unique AI-driven combinatorial analytics platform.
Our approach is unparalleled in its ability to identify causal disease biology, stratify patient populations by the molecular mechanisms of their disease, and accurately predict lifetime risk of disease to intervene early, treat effectively and prevent before onset of symptoms.
Our insights, diagnostic tools and R&D programs hold the key to reducing the global burden of chronic diseases, increasing the rate of successful drug development, and improving healthspan for billions of people.
